An arabinogalactan from fruits of Lycium barbarum L. inhibits production and aggregation of Aβ42. (1st September 2018) - Zhou, Lishuang
Highlights: A novel arabinogalactan LBP1A1-1 was purified from fruits of Lycium barbarum L. Backbone of LBP1A1-1 was 1, 4-linked α-Glc p, 1, 3- and 1, 6-linked β-Gal p . The branches contain T- and 1, 5-linked Ara f, T-linked β-Gal p and T-linked β-Rha p . LBP1A1-1 can inhibit production and aggregation of A β 42 without cytotoxicity. Abstract: The β amyloid (A β ) induced neurodegeneration is believed to be one of pathological mechanisms of Alzheimer's disease (AD). The inhibition of A β production or aggregation is one of the promising therapeutic strategies for anti-AD drug discovery. Here, a homogeneous neutral polysaccharide designated LBP1A1-1 with an average molecular weight of 45.0 kDa was purified from fruits of Lycium barbarum L. Its structure was characterized to possess a backbone of 1, 3-linked β-Gal p, 1, 6-linked β-Gal p, 1, 4-linked α-Glc p with branches substituted at C-3 position of 1, 6-linked β-Gal p or C-6 position of 1, 3-linked β-Gal p . The branches contained terminal (T)-linked β-Gal p, T-linked α-Ara f, T-linked β-Ara f, 1, 5-linked α-Ara f and T-linked β-Rha p . The in vitro experiments revealed that LBP1A1-1 could inhibit A β 42 production and impede A β 42 aggregation in a dose-dependent-manner without cytotoxicity. These results suggested that LBP1A1-1 might have the multiple potential for the treatment of AD.